Lisa Wang
YOU?
Author Swipe
View article: Combination of Shake Table Experiments and Computer Simulation to Enhance Structural Engineering Curriculum in Earthquake Engineering
Combination of Shake Table Experiments and Computer Simulation to Enhance Structural Engineering Curriculum in Earthquake Engineering Open
View article: Maveropepimut-S, Pembrolizumab and Low-dose Cyclophosphamide in Patients with Metastatic Ovarian Cancer: Final Results from Phase 1/2 PESCO trial
Maveropepimut-S, Pembrolizumab and Low-dose Cyclophosphamide in Patients with Metastatic Ovarian Cancer: Final Results from Phase 1/2 PESCO trial Open
Background: Epithelial ovarian cancer (EOC) is characterized by a pattern of relapse and progression through successive recurrences, with increasing chemotherapy resistance. This highlights an urgent need for novel treatment strategies. Su…
View article: Supplementary Figure S2 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Figure S2 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Figure S2: Figure 7: Mean ± SD concentration versus time profiles of AR (ADC), total antibody, DM4, and DM4-Me after administration of AR at 2.2 mg/kg IV x 1 plus Bev 10mg/kg IV.
View article: Supplementary Data S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Data S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
trial protocol
View article: Data from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Data from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Purpose:Mesothelin (MSLN) is highly expressed in high-grade serous/endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody–drug conjugate directed at the MSLN antigen with a tubulin polymerization inhibitor. We assesse…
View article: Supplementary Table S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Table S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Representativeness of Study Participants
View article: Supplementary Table S3 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Table S3 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
: Pharmacokinetic parameters of AR after administration of 2.2 mg/kg AR at 2.2 mg/kg IV x 1 plus Bev 10mg/kg IV.
View article: Supplementary Table S2 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Table S2 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Treatment-related AEs (Any grade)
View article: Supplementary Figure S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Figure S1 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Figure S1: Study Scheme
View article: Supplementary Figure S3 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Supplementary Figure S3 from Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Figure S3. Relationship between anetumab ravtansine AUC0-inf (A) and DM4 AUC0-168h (B) and best antitumor response.
View article: Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer Open
Background Antiangiogenics combined with immune checkpoint blockade have become standard of care for recurrent endometrial cancer after standard platinum-based chemotherapy. To dissect mechanisms and define biomarkers associated with clini…
View article: Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial) Open
Purpose: Mesothelin (MSLN) is highly expressed in high-grade serous/endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody–drug conjugate directed at the MSLN antigen with a tubulin polymerization inhibitor. We assess…
View article: Characterizing mutation-treatment effects using clinico-genomics data of 78,287 patients with 20 types of cancers
Characterizing mutation-treatment effects using clinico-genomics data of 78,287 patients with 20 types of cancers Open
View article: Supplementary Data1 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma
Supplementary Data1 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma Open
Supplemental Tables and Protocol Description
View article: Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma
Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma Open
Supplemental Figure 3. Representative baseline pre-treatment tumor specimen of a patient with AITL (H&E, ICOS staining and CD3 staining by IHC)
View article: Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma
Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma Open
Supplemental Figure 1. CD4 count recovery after end of treatment (by local site collection)
View article: Supplementary Data1 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma
Supplementary Data1 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma Open
Supplemental Tables and Protocol Description
View article: Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma
Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma Open
Supplemental Figure 3. Representative baseline pre-treatment tumor specimen of a patient with AITL (H&E, ICOS staining and CD3 staining by IHC)
View article: Data from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma
Data from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma Open
Purpose: Proliferation of T-follicular helper (TFH) CD4+ T-cells is a postulated pathogenic mechanism for T-cell non-Hodgkin’s lymphomas (T-NHL). The inducible T-cell costimulator (ICOS) is highly expressed by TFH, re…
View article: Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma
Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma Open
Supplemental Figure 1. CD4 count recovery after end of treatment (by local site collection)
View article: Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma
Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma Open
Supplemental Figure 2. MEDI-570 effects on lymphocyte and leukocyte populations. Baseline-normalized, absolute counts (ABS) of circulating cell populations were plotted on study days 1, 7, 14 and 21 from patients enrolled in each dose grou…
View article: Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma
Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma Open
Supplemental Figure 2. MEDI-570 effects on lymphocyte and leukocyte populations. Baseline-normalized, absolute counts (ABS) of circulating cell populations were plotted on study days 1, 7, 14 and 21 from patients enrolled in each dose grou…
View article: Method for Coupled Electromagnetic and Circuit Simulations to Evaluate Surge Arrester Performance in Protecting Equipment Against E1 HEMP
Method for Coupled Electromagnetic and Circuit Simulations to Evaluate Surge Arrester Performance in Protecting Equipment Against E1 HEMP Open
Surge arrester behavioral modeling for realistic systems embedded in an E1 high-altitude electromagnetic pulse environment inherently encompasses three interconnected complications: (1) the need to account for signal propagation across two…
View article: Corrigendum to Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences
Corrigendum to Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences Open
View article: Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients
Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients Open
View article: Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the <scp>GEMS</scp>‐001 clinical trial
Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the <span>GEMS</span>‐001 clinical trial Open
Objectives We aimed to evaluate the activity of selinexor, an oral selective inhibitor of nuclear export, in patients with recurrent or metastatic salivary gland tumors (SGT). Methods GEMS‐001 is an open‐label Phase 2 study for patients wi…
View article: A nomogram model in invasive pulmonary aspergillosis diagnosis based on a retrospective study
A nomogram model in invasive pulmonary aspergillosis diagnosis based on a retrospective study Open
Backgroud: With the easing of governmental COVID-19 restrictions, an upward trend was found for Aspergillus isolation in hospitalized patients . Objectives: Our research aims to analyze the clinical significance of Aspergillus positivity i…
View article: A Systematic Approach for Estimating High-Altitude Electromagnetic Pulse Coupling onto Power Generation Facility Equipment
A Systematic Approach for Estimating High-Altitude Electromagnetic Pulse Coupling onto Power Generation Facility Equipment Open
A systematic approach is presented to evaluate the effects of high-altitude electromagnetic pulse (HEMP) signals on the equipment located inside a power generation facility. The approach uses a combination of practical measurement and simu…
View article: Metal organic frameworks comprising a plurality of SBUS with different metal ions and/or a plurality of organic linking ligands with different functional groups
Metal organic frameworks comprising a plurality of SBUS with different metal ions and/or a plurality of organic linking ligands with different functional groups Open
The disclosure provides for metal organic frameworks (MOFs) which comprise a plurality of SBUs comprising different metals or metal ions and/or a plurality of organic linking moieties comprising different functional groups.
View article: Estimation of High-Altitude Electromagnetic Pulse Coupling onto Power Generation Facility Equipment
Estimation of High-Altitude Electromagnetic Pulse Coupling onto Power Generation Facility Equipment Open
A systematic approach is presented to evaluate the effects of high-altitude electromagnetic pulse (HEMP) signals on the equipment located inside a power generation facility. The technique is based on a combination of practical measurement …